Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Apellis Pharmaceuticals (APLS) Finished Goods (2021 - 2024)

Apellis Pharmaceuticals filings provide 4 years of Finished Goods readings, the most recent being $13.0 million for Q1 2024.

  • For the quarter ending Q1 2024, Finished Goods rose 325.22% year-over-year to $13.0 million, compared with a TTM value of $13.0 million through Mar 2024, up 325.22%, and an annual FY2023 reading of $30.7 million, up 1639.18% over the prior year.
  • Finished Goods hit $13.0 million in Q1 2024 for Apellis Pharmaceuticals, down from $30.7 million in the prior quarter.
  • The five-year high for Finished Goods was $30.7 million in Q4 2023, with the low at $479000.0 in Q4 2021.
  • Median Finished Goods over the past 4 years was $2.4 million (2022), compared with a mean of $9.4 million.
  • The sharpest move saw Finished Goods skyrocketed 268.68% in 2022, then skyrocketed 2909.64% in 2023.
  • Year by year, Finished Goods stood at $479000.0 in 2021, then soared by 268.68% to $1.8 million in 2022, then surged by 1639.18% to $30.7 million in 2023, then crashed by 57.57% to $13.0 million in 2024.
  • According to Business Quant data, Finished Goods over the past three periods came in at $13.0 million, $30.7 million, and $20.3 million for Q1 2024, Q4 2023, and Q3 2023 respectively.